Donor lymphocyte infusion (DLI) of T-cells genetically modified with iCasp9 suicide gene
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donor lymphocyte infusion (DLI) of T-cells genetically modified with iCasp9 suicide gene, covering 2019-07-16 to 2019-07-16. Get the full timeline:
Most recent: Clinical Trial Update: Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene [Phase 1, Phase 2]